About: Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scholarly article by Stephen K Field published 30 April 2008 in Expert Opinion on Investigational Drugs

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована у квітні 2008 (uk) im April 2008 veröffentlichter wissenschaftlicher Artikel (de) scholarly article by Stephen K Field published 30 April 2008 in Expert Opinion on Investigational Drugs (en)
publication date	wds:Q56909272-8F51C3CB-FD36-49A3-9589-DDD3B61C68B8
publication date	2008-04-30 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q56909272-A5C13B1E-2BA4-40D8-B86C-977ECD87E941
language of work or name	English
cites work	wds:Q56909272-01013110-A9F7-4107-AEA7-39E6D17C2C5E wds:Q56909272-0F327D34-603E-422A-AAFE-360334F04BB4 wds:Q56909272-17A74B10-CF2F-4215-BDA6-850BF4B96CBC wds:Q56909272-21E04F50-32D5-46C7-9458-5627385B9E80 wds:Q56909272-2296D731-E060-4190-9F4C-495764E7D80A wds:Q56909272-356A6B2D-018B-41C0-B2BB-CBE86DEE548B wds:Q56909272-356E1B5C-A119-4B5A-BD9C-F2EC91355CF2 wds:Q56909272-365A0CE8-DF29-4A6B-B9F5-CC221FFC3AD6 wds:Q56909272-4BFD79C2-FEAC-4B8D-9DB7-E1D00B5B1459 wds:Q56909272-55B43C76-6A97-4F4E-A7CD-ABF2D1B22BF5 wds:Q56909272-575A492C-8057-4881-8F53-B4ECF4C4FF61 wds:Q56909272-5CCC9AF8-612B-44AF-A0A2-CFCE758A1F7C wds:Q56909272-5FDCB6B5-2624-4554-AF11-B8AB9B03982B wds:Q56909272-61DBAC23-D299-4F1D-B98D-CCA390A05A46 wds:Q56909272-67818D86-34AC-414A-BD3E-35BDFA77930C wds:Q56909272-72E07A65-5F07-4642-9ABD-44C59BD28A54 wds:Q56909272-81EE9255-5E19-492C-A96C-E1837B16777D wds:Q56909272-84C9FEBA-D77C-4254-8A1E-7B464FDE8BF8 wds:Q56909272-9192FFA3-2C08-4C93-852E-ABFAC01C7500 wds:Q56909272-920A136A-4A59-448F-A386-DD504EBAA8AA wds:Q56909272-92A1AA31-5E88-4CCA-A0B8-31ADA651540D wds:Q56909272-A4F9327B-00A2-446F-BE24-4B1D74B4E62C wds:Q56909272-A93A76C8-06E5-4BCB-BCE1-8D5CE89081E4 wds:Q56909272-AFC1B5A4-3DFE-4A72-93CC-D21106AA3727 wds:Q56909272-BEEFF67C-1224-4111-B59D-6107DEB02159 wds:Q56909272-CBFBE7AF-D306-42A6-B30E-1F6FC542067A wds:Q56909272-D0A204C1-CF16-4449-8DB0-FA98F40FD3B9 wds:Q56909272-D19A59DC-4CB3-4E33-A513-E1DB0A4E58BE wds:Q56909272-D3262870-644F-4A0B-AC33-78321869C2DE wds:Q56909272-DDD06FBB-70D3-4C9C-B914-351C4B3BC827 wds:Q56909272-E36DFD25-28A7-49EC-815E-FF3459F8E785 wds:Q56909272-F4DF7AEE-1BEB-400A-A5A3-C542A22DAAEB wds:Q56909272-F5A816D5-75B4-4A65-9986-F93208A70CE1 wds:Q56909272-FD159F8F-B27B-4EA9-A973-AF642ED27DA4
cites work	The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo Trends in the leading causes of death in the United States, 1970-2002. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial The nature of small-airway obstruction in chronic obstructive pulmonary disease The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease. Systemic effects of chronic obstructive pulmonary disease: what we know and what we don't know (but should). Differences in airway cytokine profile in severe asthma compared to moderate asthma. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids Theophylline: new perspectives for an old drug Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD Phosphodiesterase isozymes: molecular targets for novel antiasthma agents Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease Roflumilast inhibition of pulmonary leukotriene production and bronchoconstriction in ovalbumin-sensitized and -challenged Guinea pigs Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease Pathophysiology of airflow limitation in chronic obstructive pulmonary disease Structural basis for the activity of drugs that inhibit phosphodiesterases Theophylline for COPD. The phosphodiesterase 4 inhibitor roflumilast is effective in the treatment of allergic rhinitis Safety of inhaled corticosteroids Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects. Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability. Airway inflammation in severe chronic obstructive pulmonary disease: relationship with lung function and radiologic emphysema. Inhaled corticosteroids in chronic obstructive pulmonary disease Are phosphodiesterase 4 inhibitors just more theophylline? Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions A 1-year prospective cost-effectiveness analysis of roflumilast for the treatment of patients with severe chronic obstructive pulmonary disease.
rdfs:label	Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma (en) Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma (nl)
skos:prefLabel	Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma (en) Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma (nl)
name	Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma (en) Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma (nl)
author	wds:Q56909272-852F36E1-7000-4F1B-8941-385B8E0FD822
author	Stephen K Field
title	wds:Q56909272-F1B29D58-446C-45E9-9142-E07AB0D175B1
title	Roflumilast: an oral, once-daily selective PDE-4 inhibitor for the management of COPD and asthma (en)
page(s)	wds:Q56909272-9936F58C-E8FC-4B52-B2B0-D5CA196C1F39
page(s)	811-818
instance of	wds:Q56909272-C587062E-E4F1-45B1-8DF5-257BE8179687 wds:Q56909272-e2792be5-02c7-47a8-a57e-73eb1e5fb427
instance of	review article scholarly article
main subject	wds:Q56909272-68645690-8876-4AF6-B8EE-B6B7E675EA95 wds:Q56909272-C3550F28-0AEB-45AB-975C-DED5E87F5396
main subject	chronic obstructive pulmonary disease asthma
PubMed ID	wds:Q56909272-FD4871CC-09BF-4043-BF5A-5A534EBA4ACD
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/18447606
PubMed ID	18447606

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software